Peptide Conjugates Of Splice-correcting Oligonucleotides For Enhanced In Vitro And In Vivo Delivery For Neuromuscular Disease Therapy.
Funder
National Health and Medical Research Council
Funding Amount
$332,347.00
Summary
Currently, there is no known cure for certain neuromuscular genetic disorders. However, recently identified synthetic DNA-type biomolecules have shown promising results in reversing such diseases in mice. These biomolecules cannot easily enter the cells in high enough quantity to elicit their beneficial effects. Therefore, this project will aim at identifying novel vecotrs that, when coupled to these biomolecules, are capable of delivering them into specific cell types as well as into the brain.
Development Of Specific Modulators Of Voltage-gated Sodium Channels
Funder
National Health and Medical Research Council
Funding Amount
$384,479.00
Summary
This project will identify novel modulators of voltage-gated sodium (NaV) channels, a type of sodium-conducting integral membrane proteins, which play a central role in neuronal, muscular, and cardiac function. These modulators will be characterized in order to understand how they modify channel function and to aid their development as analgesics for the treatment of chronic pain.
Structural Investigation Of The Major Histocompatibility Complex Class I Peptide-loading Complex
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
The identification and destruction of diseased cells by our immune system is essential to controlling the spread of infection. This proposal is aimed at the characterisation of the peptide-loading complex (PLC), a large molecular machine that facilitates a crucial step in the process of ‘flagging’ infected cells. Determining the 3D structures of its key components, as well the way in which they interact will help us understand how the PLC contributes to maintaining our body’s health.
The Potential Of Blocking Translation Initiation For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$347,792.00
Summary
Treatment of many cancers remains unsatisfactory and new drugs for treating them are urgently required. By determining how a new class of anti-cancer drugs kills cancer cells and whether they might also affect normal cells, we can determine how they can be optimally given to patients suffering from cancer.